Illuminating Immunohistochemistry: Right-sizing Your Validation and Regulatory Strategy

Watch Now

Sponsored by:

Precision for Medicine
Date:
October 2, 2024
Time (PT):
5:00 PM

Webinar Highlights

This session will explore in-depth the essential validation and regulatory strategies for IHC, providing crucial insights into the regulatory landscape and validation processes necessary for successful clinical trials.Our expert speakers, Kennon Daniels, PhD, a scientific and regulatory in vitro diagnostic authority from Precision for Medicine, and Christie Bongel, MS, CT(ASCP), an experienced site director specializing in cytology and molecular diagnostics at Precision for Medicine, will guide you through the complexities of regulatory requirements, ensuring your IHC assays are compliant and optimized for clinical use. Topics include foundational laws and standards, aligning your validation and regulatory strategies with US clinical trial goals, and understanding regulatory differences between the US and Europe.

Key Takeaways:

  • Foundational Overview of Applicable Laws and Standards: Understand key regulations, including CLIA, CLSI, GCLP, and ISO, and their relevance to IHC.
  • Mapping Your US Regulatory Path: Learn how to align your validation and regulatory strategy with your clinical trial goals in the US.
  • Navigating Regulatory Differences: Gain a high-level overview of the regulatory differences between the US and Europe, focusing on IHC in clinical trials.
  • Utilizing Assays in Clinical Trials: Explore how assays are used in clinical trials, including exploratory biomarkers and patient enrollment.

Don't miss this opportunity to enhance your knowledge and ensure your IHC assays are fully compliant and optimized for clinical success. Register now!To watch the first installment of the webinar series, click here.

Presenters

Kennon Daniels

Precision for Medicine (IVD Regulatory Consulting)
Vice President

Kennon Daniels is a scientific and regulatory in vitro diagnostic authority, specializing in the development of US regulatory strategies and FDA marketing submissions for IVD assays and instruments. Her expertise spans all aspects of product development, analytical and clinical trial protocol designs, Q-Submissions, IDEs, de novos, 510(k)s, and pre-market approval platforms.

Read More

Christie Bongel

Precision for Medicine
Site Director - Histology

Christie Bongel, MS, CT(ASCP), brings nearly two decades of experience in both research and clinical medicine. As the site director for Precision for Medicine’s IHC Center of Excellence in North Carolina, she excels in managing scientific operations and collaborating with clients. Christie is skilled in cytology, laboratory medicine, and molecular diagnostics. Her role focuses on building an energized team dedicated to delivering life-changing outcomes for patients. Christie earned her MS in Applied Biotechnology and is an ASCP certified cytotechnologist.

Read More

Sponsor

Precision for Medicine

Precision for Medicine is an industry-leading global CRO, specifically designed to apply a biomarker-focused, precision medicine approach to therapeutic development.

Content Partners

Scientist.com

Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.

We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.

Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.

Related Content

Related Content